<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks. Deshpande reflects on his previous experience developing and commercializing Dupixent at Sanofi, describes the history and mechanism of Immediate's glucose-insulin-potassium (GIK) candidate, IMT-358, and explains why there is more to intellectual property than just patents. Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.

Business Of Biotech

AI Chapters

AI Insights

Reviews